Thursday, 23 October 2014
|NZX : PEB|
22 Oct 14 00:00
Pacific Edge is a New Zealand based biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer.
Two products have recently completed successful clinical trials, bladder cancer detection and colorectal cancer prognosis (CRC). The bladder cancer technology Cxbladder® has been released to the market in Australia and New Zealand. CRC is being readied for commercial release. Pipeline products still in development include gastric and endometrial cancers and melanoma.
Cxbladder® is a non-invasive, accurate test that enables the early detection of bladder cancer from a small volume of urine providing general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy.
The Company is commercialising its products from its new diagnostic laboratory in New Zealand and plans further commercialisation in the US and Europe as a centralised diagnostic service through its own facilities or as a turn-key solution, licensed to selected partners. Pacific Edge has plans for further studies in key markets to engage leading medical and urological opinion leaders who will be vital to success in new markets.
|Issuer:||Pacific Edge Limited|
|Solicitor:||Anderson Lloyd Caudwell Dunedin|
|Registry:||LINK MARKET SERVICES LIMITED|
|Auditor:||Pricewaterhouse Coopers Dunedin|
|Settlement:||NZCDC Settlement System|
|52 wk High:||1.7600|
|52 wk Low:||0.6200|
Pacific Edge Limited
87 St David Street
02:06 | 23/10/14
Today, Analysts Review released its research reports regarding Wal-Mart Stores, Inc. WMT, +0.28% Union Pacific Corporation UNP, -0.80% eBay Inc. EBAY, +1.41% McDonald's Corporation MCD, +0.03% and The Home Depot, Inc. HD, +0.58% Private wealth members ... more»
11:41 | 22/10/14
Motley Fool Australia
Recent earnings declines across most of Ausdrill's business lines and the subsequent revision to expected profit for the year tipped shareholders over the edge and sent Ausdrill down from recent prices of $1.30 in August to the current low of 73 cents. more»
Following is the unofficial transcript of a CNBC EXCLUSIVE interview with Greenlight Capital Co-Founder and President David Einhorn today on CNBC's "Fast Money Halftime Report" (M-F, 12PM-1PM ET). more»
05:07 | 22/10/14
This was made apparent again last week when WikiLeaks revealed a new draft of the Trans-Pacific-Partnership agreement. This treaty is currently being negotiated between about a dozen Pacific Rim countries, including the US, Canada, Malaysia, Japan and ... more»
22:33 | 21/10/14
Panellists included Farah Foustok, Managing Director and Senior Executive Officer of Lazard Gulf Ltd; Nesreen Srouji, Head of Sovereign Wealth Fund Coverage for the MENA region at Standard Chartered Bank; Amel Murphy, Co-founder of Sustain Leadership ... more»
NOTICE OF CHANGE IN ISSUED CAPITAL STOCK - ORDINARY SHARES
Pursuant to Listing Rule 7.3.5
Company: Pacific Edge Limited ISIN NZPEBE0002S1
Date: 5 July 2013
Date of Is more»
NOTICE OF APPOINTMENT OF INDEPENDENT DIRECTOR
Pursuant to Listing Rule 3.3
Date: 4 July 2013
Company: Pacific Edge Limited
Pacific Edge Limited is pleased to announce that more»
Please find attached the 2013 Annual Report.
End CA:00237882 For:PEB Type:ANNREP Time:2013-06-27 10:47:29 more»
See attached presentation
End CA:00237343 For:PEB Type:ADDRESS Time:2013-06-13 09:52:00 more»
PRELIMINARY FULL YEAR DISCLOSURE
Pacific Edge Limited
Year End 31 March 2013
FY2013 Results Summary
- Sales and marketing of Cxbladder launched in the USA - the world''s larg more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW